Researchers find promising new way to boost the immune response to cancer

Multi-pronged antibodies more effective in activating cancer-killing cells

Researchers at the University of Southampton have developed a promising new way to bolster the body’s immune system response to cancer.

In a study published in Nature Communications, researchers used specially engineered multi-pronged antibodies to better activate cancer-killing T cells.

The antibodies work by ‘grabbing’ and ‘clustering’ multiple immune cell receptors – boosting the signal which tells the T cell to attack the cancer.

The team from the University of Southampton’s Centre for Cancer Immunology focused their efforts on an immune receptor called CD27. CD27 needs a matching key (ligand) to activate T cells. This ligand is produced naturally in response to infection, but cancers lack this signal and T cells can only elicit a weak response against the cancer cells.

Antibodies can work a bit like a master key, but most commonly used antibodies are Y-shaped molecules with two prongs, meaning they can only engage two receptors at the same time.

While antibodies have revolutionised cancer treatment, some cancers don’t respond because T cells don’t receive all the signals they need to become fully active. 

The antibodies developed by the researchers have four prongs, allowing them to grab onto more receptors. They also enlist the help of a second cell, forcing all the CD27 receptors they are holding to clump together. This amplifies the signal and mimics the natural way CD27 is activated in the body.

Professor Aymen Al‑Shamkhani at the University of Southampton, who led the study, explains: “We already understood how the body’s natural CD27 signal switches on T cells, but turning that knowledge into a medicine was the real challenge. Antibodies are reliable molecules that make excellent drugs. However, the natural antibody format was not powerful enough, so we had to create a more effective version.”

In lab studies using mice as well as human immune cells, the new antibodies were more effective in switching on CD8⁺ T cells – the ‘special forces’ of the immune system, than standard Y-shaped antibodies, delivering a more robust anti-tumour response.

By making CD27 more responsive to therapeutic targeting, the findings provide a blueprint for developing next‑generation immunotherapies that harness the immune system to fight cancer more effectively.

Professor Al‑Shamkhani said: “This approach could help improve future cancer treatments by allowing the immune system to work closer to its full potential.”

The research was funded by Cancer Research UK and highlights the Centre for Cancer Immunology’s role in advancing innovative cancer immunotherapies.

Harnessing Multivalency and FcγRIIB Engagement to Augment Anti-CD27 Immunotherapy is published in Nature Communications and is available online.

Ends

Contact

Steve Williams, Media Manager, University of Southampton, press@soton.ac.uk or 023 8059 3212.

Notes for editors

1. Harnessing Multivalency and FcγRIIB Engagement to Augment Anti-CD27 Immunotherapy is published in Nature Communications. It is available here: https://www.nature.com/articles/s41467-025-67882-3
2. For interviews with Professor Aymen Al-Shamkhani, please contact Steve Williams, Media Manager, University of Southampton press@soton.ac.uk or 023 8059 3212.
3. Image caption: A microscopy image depicting immune receptor distribution analysis in human T cells. The same-coloured spots represent receptors that are clumped together in a single cluster. This image is made by superimposing two different images from two different techniques. One that ‘slices’ through the cell to show clusters on the periphery and a super-resolution technique that gives higher resolution of the clusters (the coloured spots). Credit University of Southampton.

Additional information

The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world’s challenges. We are among the top 100 institutions globally (QS World University Rankings 2025). Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 24,000-strong community of exceptional students, from over 135 countries worldwide. Through our high-quality education, the University helps students on a journey of discovery to realise their potential and join our global network of over 300,000 alumni. www.southampton.ac.uk

www.southampton.ac.uk/news/contact-press-team.page

Follow us on X: https://twitter.com/UoSMedia